ArticleFrontiers in pharmacology2024
Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think.Kidney medicine · 2026Article
- Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients.Frontiers in immunology · 2026Article
- Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Acute post-infusion hypokalemia following rituximab therapy in patients with nephrotic syndrome: case series and literature review.Frontiers in pharmacology · 2026Article
- Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.Clinical kidney journal · 2025Review
- Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase AFrontiers in immunology · 2025Article
- Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.Drug design, development and therapy · 2025Article
- Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.Drugs in context · 2025Review
- Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.Kidney international reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) is a monoclonal antibody commonly used to treat PLA2R-associated membranous nephropathy (MN). This report presents a case of refractory MN in a patient who experienced severe hypokalemia, a rare but clinically significant condition, after the 5th RTX infusion. Clinicians should be aware of the potential for hypokalemia and its management during or after RTX infusion. After the onset of hypokalemia, the patient received treatment with obinutuzumab and achieved partial remission of renal disease without experiencing further hypokalemia. Obinutuzumab may be a viable alternative therapy for refractory membranous nephropathy that develops side effects after rituximab therapy or is refractory to it, but further studies are necessary to determine its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.